Cargando…

MEDB-90. Iron Imbalance Can Potentiate Cisplatin Response in Pediatric Medulloblastoma by Regulating Ferroptosis

Medulloblastoma (MB), the most common malignant pediatric brain tumor, is a leading cause of childhood mortality. Of the four primary subgroups, patients with group 3 tumors have the poorest prognosis. Loss of chromosome 17p is a high-risk feature associated with poor outcomes in group 3 tumors. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanchan, Ranjana, Perumal, Naveenkumar, Khan, Parvez, Doss, David, Venkata, Ramakanth Chirravuri, Thapa, Ishwor, Vengoji, Raghupathy, Kaushal, Jyoti, Siddiqui, Jawed, Nasser, Mohd Wasim, Batra, Surinder, Mahapatra, Sidhartha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164725/
http://dx.doi.org/10.1093/neuonc/noac079.464
_version_ 1784720204093194240
author Kanchan, Ranjana
Perumal, Naveenkumar
Khan, Parvez
Doss, David
Venkata, Ramakanth Chirravuri
Thapa, Ishwor
Vengoji, Raghupathy
Kaushal, Jyoti
Siddiqui, Jawed
Nasser, Mohd Wasim
Batra, Surinder
Mahapatra, Sidhartha
author_facet Kanchan, Ranjana
Perumal, Naveenkumar
Khan, Parvez
Doss, David
Venkata, Ramakanth Chirravuri
Thapa, Ishwor
Vengoji, Raghupathy
Kaushal, Jyoti
Siddiqui, Jawed
Nasser, Mohd Wasim
Batra, Surinder
Mahapatra, Sidhartha
author_sort Kanchan, Ranjana
collection PubMed
description Medulloblastoma (MB), the most common malignant pediatric brain tumor, is a leading cause of childhood mortality. Of the four primary subgroups, patients with group 3 tumors have the poorest prognosis. Loss of chromosome 17p is a high-risk feature associated with poor outcomes in group 3 tumors. We recently elucidated the tumor suppressive properties of a novel miR, miR-1253, on the terminal end of 17p. In further exploring its anti-neoplastic effects, we discovered that miR-1253 can disrupt iron homeostasis, causing oxidative stress and inducing lipid peroxidation. These concurrent events are capable of triggering an iron-mediated form of cell death called ferroptosis. Notably, our in silico interrogation of ferroptosis regulator genes (FRGs) in group 3 tumors revealed high expression of genes associated with iron transport and glutathione metabolism. These included mitochondrial iron transporters and GPX4, a critical regulator of ferroptosis. Restoration of miR-1253 expression in group 3 cell lines resulted in specific downregulation of ABCB7, an iron-sulfur cluster exporter, and GPX4. Consequently, cytosolic and mitochondrial labile iron pools rose, glutathione levels declined, and mitochondrial oxidative stress and lipid peroxidation were induced. These events were recapitulated by ABCB7 knockdown and potentiated cell death. Treating miR-1253-expressing cancer cells with cisplatin, a group 3 MB chemotherapeutic agent with ferroptotic properties, further elevated oxidative stress, depleted glutathione levels, and augmented lipid peroxidation, with added inhibitory effects on cell viability and colony formation. Treatment with a ferroptosis inhibitor (ferrostatin-1) lead to recovery from the cytotoxic effects of this combination therapy. Our studies highlight a novel mechanism for group 3 MB pathogenesis via ferroptosis regulation and provide a proof-of-concept for exploiting group 3 MB tumor vulnerability to iron imbalance as a novel treatment strategy.
format Online
Article
Text
id pubmed-9164725
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-91647252022-06-05 MEDB-90. Iron Imbalance Can Potentiate Cisplatin Response in Pediatric Medulloblastoma by Regulating Ferroptosis Kanchan, Ranjana Perumal, Naveenkumar Khan, Parvez Doss, David Venkata, Ramakanth Chirravuri Thapa, Ishwor Vengoji, Raghupathy Kaushal, Jyoti Siddiqui, Jawed Nasser, Mohd Wasim Batra, Surinder Mahapatra, Sidhartha Neuro Oncol Medulloblastoma Medulloblastoma (MB), the most common malignant pediatric brain tumor, is a leading cause of childhood mortality. Of the four primary subgroups, patients with group 3 tumors have the poorest prognosis. Loss of chromosome 17p is a high-risk feature associated with poor outcomes in group 3 tumors. We recently elucidated the tumor suppressive properties of a novel miR, miR-1253, on the terminal end of 17p. In further exploring its anti-neoplastic effects, we discovered that miR-1253 can disrupt iron homeostasis, causing oxidative stress and inducing lipid peroxidation. These concurrent events are capable of triggering an iron-mediated form of cell death called ferroptosis. Notably, our in silico interrogation of ferroptosis regulator genes (FRGs) in group 3 tumors revealed high expression of genes associated with iron transport and glutathione metabolism. These included mitochondrial iron transporters and GPX4, a critical regulator of ferroptosis. Restoration of miR-1253 expression in group 3 cell lines resulted in specific downregulation of ABCB7, an iron-sulfur cluster exporter, and GPX4. Consequently, cytosolic and mitochondrial labile iron pools rose, glutathione levels declined, and mitochondrial oxidative stress and lipid peroxidation were induced. These events were recapitulated by ABCB7 knockdown and potentiated cell death. Treating miR-1253-expressing cancer cells with cisplatin, a group 3 MB chemotherapeutic agent with ferroptotic properties, further elevated oxidative stress, depleted glutathione levels, and augmented lipid peroxidation, with added inhibitory effects on cell viability and colony formation. Treatment with a ferroptosis inhibitor (ferrostatin-1) lead to recovery from the cytotoxic effects of this combination therapy. Our studies highlight a novel mechanism for group 3 MB pathogenesis via ferroptosis regulation and provide a proof-of-concept for exploiting group 3 MB tumor vulnerability to iron imbalance as a novel treatment strategy. Oxford University Press 2022-06-03 /pmc/articles/PMC9164725/ http://dx.doi.org/10.1093/neuonc/noac079.464 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Medulloblastoma
Kanchan, Ranjana
Perumal, Naveenkumar
Khan, Parvez
Doss, David
Venkata, Ramakanth Chirravuri
Thapa, Ishwor
Vengoji, Raghupathy
Kaushal, Jyoti
Siddiqui, Jawed
Nasser, Mohd Wasim
Batra, Surinder
Mahapatra, Sidhartha
MEDB-90. Iron Imbalance Can Potentiate Cisplatin Response in Pediatric Medulloblastoma by Regulating Ferroptosis
title MEDB-90. Iron Imbalance Can Potentiate Cisplatin Response in Pediatric Medulloblastoma by Regulating Ferroptosis
title_full MEDB-90. Iron Imbalance Can Potentiate Cisplatin Response in Pediatric Medulloblastoma by Regulating Ferroptosis
title_fullStr MEDB-90. Iron Imbalance Can Potentiate Cisplatin Response in Pediatric Medulloblastoma by Regulating Ferroptosis
title_full_unstemmed MEDB-90. Iron Imbalance Can Potentiate Cisplatin Response in Pediatric Medulloblastoma by Regulating Ferroptosis
title_short MEDB-90. Iron Imbalance Can Potentiate Cisplatin Response in Pediatric Medulloblastoma by Regulating Ferroptosis
title_sort medb-90. iron imbalance can potentiate cisplatin response in pediatric medulloblastoma by regulating ferroptosis
topic Medulloblastoma
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164725/
http://dx.doi.org/10.1093/neuonc/noac079.464
work_keys_str_mv AT kanchanranjana medb90ironimbalancecanpotentiatecisplatinresponseinpediatricmedulloblastomabyregulatingferroptosis
AT perumalnaveenkumar medb90ironimbalancecanpotentiatecisplatinresponseinpediatricmedulloblastomabyregulatingferroptosis
AT khanparvez medb90ironimbalancecanpotentiatecisplatinresponseinpediatricmedulloblastomabyregulatingferroptosis
AT dossdavid medb90ironimbalancecanpotentiatecisplatinresponseinpediatricmedulloblastomabyregulatingferroptosis
AT venkataramakanthchirravuri medb90ironimbalancecanpotentiatecisplatinresponseinpediatricmedulloblastomabyregulatingferroptosis
AT thapaishwor medb90ironimbalancecanpotentiatecisplatinresponseinpediatricmedulloblastomabyregulatingferroptosis
AT vengojiraghupathy medb90ironimbalancecanpotentiatecisplatinresponseinpediatricmedulloblastomabyregulatingferroptosis
AT kaushaljyoti medb90ironimbalancecanpotentiatecisplatinresponseinpediatricmedulloblastomabyregulatingferroptosis
AT siddiquijawed medb90ironimbalancecanpotentiatecisplatinresponseinpediatricmedulloblastomabyregulatingferroptosis
AT nassermohdwasim medb90ironimbalancecanpotentiatecisplatinresponseinpediatricmedulloblastomabyregulatingferroptosis
AT batrasurinder medb90ironimbalancecanpotentiatecisplatinresponseinpediatricmedulloblastomabyregulatingferroptosis
AT mahapatrasidhartha medb90ironimbalancecanpotentiatecisplatinresponseinpediatricmedulloblastomabyregulatingferroptosis